コメントを投稿するにはログインが必要です
ログインページへ記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#6-01E. Rewriting the Clinical Map: 2026 Consensus Guidelines on CAR T-Cell Therapy for Autoimmune Diseases (Lancet Rheumatol, 2026)
2026年10月20日 12:00·5分11秒
As CAR T-cell therapy expands beyond oncology, how can clinicians safely navigate its emerging role in severe, treatment-refractory autoimmune diseases? The updated 2026 EBMT-ISCT-JACIE consensus provides standardized expert recommendations on patient selection, lymphodepleting regimens, and monitoring across rheumatic, neurological, and hematological indications; however, current guidance remains grounded primarily in uncontrolled case series without high-quality randomized trial data. Ultimately, this framework equips clinicians with essential criteria for multidisciplinary management, patient stratification, and adverse event mitigation in daily practice.
Citation: Greco R, Müller F, Haghikia A, et al. CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations. Lancet Rheumatol. 2026.
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
